Side-by-side · Research reference
CortagenvsDihexa
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED11/35 cited
BAnimal-StrongHUMAN-REVIEWED7/28 cited
Cortagen
Bioregulatory Tetrapeptide · Khavinson-School
Injectable · Animal models
Dihexa
Angiotensin IV Analogue · Pre-Clinical
Not established — animal studies only
01Mechanism of Action
Parameter
Cortagen
Dihexa
Primary target
Cerebral cortex tissue — molecular targets under investigation
c-Met receptor (HGF receptor tyrosine kinase)
Pathway
Antioxidant pathway modulation — suppression of LPO cascade, reduction of protein oxidative modificationKozina 2007
HGF/c-Met receptor activation → downstream signaling cascade → synaptogenesis and dendritic arborization
Downstream effect
Decreased lipid peroxidation products, reduced oxidative protein damage, altered gene expression in cardiac tissueKozina 2007Anisimov 2004
Induction of dendritic arborization, synapse formation, neurogenesis, and neuroprotection in rodent models
Feedback intact?
—
—
Origin
Synthetic tetrapeptide derived from amino acid analysis of natural brain cortex peptide preparation CortexinAnisimov 2004
Small-molecule angiotensin IV analogue designed to activate HGF/c-Met systemWright 2015
Antibody development
—
—
02Dosage Protocols
Parameter
Cortagen
Dihexa
Animal model dose (rat)
Injection protocol (dose not specified in abstracts)
Multiple injections over study period.
—
Avian model dose (chicken)
40-day injection courseKuznik 2008
Compared to epithalon in hypophysectomized and aged birds.
—
Human peripheral nerve study
Therapeutic course (protocol details not provided)
Posttraumatic recovery context — reference cited but not detailed.
—
Evidence basis
Animal mechanistic studies
Pre-clinical / Rodent models
Route
Injectable (inferred from animal protocols)
—
Human dosing
—
Not established — no human trials
Animal studies
—
Mouse/rat models only — dosing not translatable to humans
Clinical status
—
No Phase 1, 2, or 3 trials published
04Side Effects & Safety
Parameter
Cortagen
Dihexa
Antioxidant suppression
Suppression of antioxidant activity noted alongside LPO reductionKozina 2007
Mechanism unclear — possible homeostatic adaptation.
—
Immune/hemostasis effects
No effect on immunity or hemostasis parameters in avian hypophysectomy model (unlike epithalon)Kuznik 2008
Epithalon reversed deficits; cortagen did not.
—
Human safety data
No adverse events reported in peripheral nerve recovery context
Limited detail in available abstracts.
None available — no human clinical trials
Theoretical c-Met risks
—
c-Met receptor activation has been implicated in tumorigenesis; unknown cancer risk profile
Pre-clinical tolerability
—
Not systematically reported in available studies
Absolute Contraindications
Cortagen
—Dihexa
- ·Not approved for human use — research compound only
Relative Contraindications
Cortagen
—Dihexa
- ·Theoretical contraindication: active or history of malignancy (c-Met pathway involvement in cancer)
05Administration Protocol
Parameter
Cortagen
Dihexa
1. Preparation
Reconstitute lyophilised peptide with bacteriostatic water per supplier protocol. Exact volumes depend on concentration supplied.
No established protocol. Dihexa has not been tested in human subjects. Animal studies used various routes (typically subcutaneous or intraperitoneal in rodents) not translatable to clinical use.
2. Injection site
Subcutaneous injection typical for bioregulatory peptides — abdomen or thigh. Rotate sites.
Pre-clinical research compound. Not approved by FDA or any regulatory authority for human use.
3. Timing
Animal protocols used repeated dosing over weeks. Human timing not established — evening administration common in Khavinson tradition.
—
4. Storage
Lyophilised: refrigerate or freeze per supplier. Reconstituted: refrigerate 2–8 °C, use within guideline window.
—